Literature DB >> 17429940

Synthesis, characterization, and in vitro activity of dendrimer-streptokinase conjugates.

Xiangtao Wang1, Rajyalakshmi Inapagolla, Sujatha Kannan, Mary Lieh-Lai, Rangaramanujam M Kannan.   

Abstract

Dendrimer conjugation with low molecular weight drugs has been of increasing interest recently for improving pharmacokinetics, targeting drugs to specific sites, and facilitating cellular uptake. Opportunities for increasing the performance of relatively large therapeutic proteins such as streptokinase (SK) using dendrimers are being explored in this study. Using the active ester method, a series of streptokinase-poly(amido amine) (PAMAM) G3.5 conjugates were synthesized with varying amounts of dendrimer-to-protein molar ratios. Characterization of these conjugates by GPC, IEC, and native-PAGE suggested that the conjugation reaction was successful, resulting in relatively pure SK-dendrimer conjugates. The conjugate made with an equimolar ratio of dendrimer to streptokinase (1:1) exhibited the highest enzymatic activity retention ( approximately 80% retained) that has been reported so far for conjugated streptokinase with macromolecules such as PEG or dextran. SK conjugates with higher streptokinase-to-dendrimer molar ratios (1:10 and 1:20) exhibited lower initial enzymatic activities. However, these conjugates showed sustained thrombolytic activity in plasma, perhaps due to the release of SK from the conjugate. All of the SK conjugates displayed significantly improved stability in phosphate buffer solution, compared to free SK. The high coupling reaction efficiencies and the resulting high enzymatic activity retention achieved in this study could enable a desirable way for modifying many bioactive macromolecules with dendrimers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429940     DOI: 10.1021/bc060322d

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  8 in total

Review 1.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  In quest of a systematic framework for unifying and defining nanoscience.

Authors:  Donald A Tomalia
Journal:  J Nanopart Res       Date:  2009-05-26       Impact factor: 2.253

Review 3.  An update on smart biocatalysts for industrial and biomedical applications.

Authors:  Akhilesh Kumar Shakya; Kutty Selva Nandakumar
Journal:  J R Soc Interface       Date:  2018-02       Impact factor: 4.118

Review 4.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

5.  A bioconjugated polyglycerol dendrimer with glucose sensing properties.

Authors:  Edson Giuliani Ramos Fernandes; Alvaro Antonio Alencar De Queiroz
Journal:  J Mater Sci Mater Med       Date:  2008-10-14       Impact factor: 3.896

6.  Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.

Authors:  Andrzej S Pitek; Yunmei Wang; Sahil Gulati; Huiyun Gao; Phoebe L Stewart; Daniel I Simon; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2017-09-26       Impact factor: 4.939

7.  Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.

Authors:  Xiangji Chen; Shuping Dou; Guozheng Liu; Xinrong Liu; Yi Wang; Ling Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-07-23       Impact factor: 4.774

Review 8.  Engineered microparticles and nanoparticles for fibrinolysis.

Authors:  Dante Disharoon; David W M Marr; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-10-07       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.